2018 American Transplant Congress
Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes
University of Wisconsin, Madison.
PJP after transplant (TX) is associated with substantial morbidity and mortality. In the present era of universal and routine implementation of PJP prophylaxis (PPX) during…2018 American Transplant Congress
Impact of Pneumocystis Prophylaxis on Incidence of Treated Urinary Tract Infections Following Kidney Transplantation
Rush University Medical Center, Chicago, IL.
Background: Urinary tract infection (UTI) is the most common infectious complication after kidney transplantation resulting in increased morbidity and mortality. Sulfamethoxazole[mdash]trimethoprim (SMX-TMP) is commonly used…2018 American Transplant Congress
Standard- versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients
Henry Ford Hospital, Detroit, MI.
Background: Although guidelines recommend valganciclovir (VGC) 900 mg daily for cytomegalovirus (CMV) prophylaxis in solid organ transplant patients, multiple centers have reported clinical success, reduced…2017 American Transplant Congress
Antibiotic Prophylaxis Against Urinary Tract Infections After Renal Transplant.
1Pharmacy, University of Colorado, Aurora, CO; 2Nephrology, University of Colorado, Aurora, CO
Urinary tract infections (UTI) are the most common infectious complication after kidney transplant. Previous research at our center showed sulfamethoxazole/trimethoprim (SMX/TMP) use for PCP prophylaxis…2017 American Transplant Congress
Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.
Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…2017 American Transplant Congress
Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate Risk Renal Transplants: A Single Center Experience.
1Infectious Diseases, Yale University, New Haven, CT; 2Pharmacy, YNHH, New Haven, CT
IntroductionCurrent guidelines on cytomegalovirus (CMV) prophylaxis following organ transplant recommend using valganciclovir (VGCV) 900 mg daily for high (CMV D+/R-) and intermediate (CMV R+) risk…2017 American Transplant Congress
High-Dose Acyclovir for Cytomegalovirus Prevention in Seropositive Solid Organ Transplant Recipients.
Purpose: Evaluate the incidence of cytomegalovirus (CMV) infection in seropositive (R+) solid organ transplant recipients (SOT) receiving high-dose acyclovir (HD-A, 800 mg QID) prophylaxis.Methods: Retrospective…2017 American Transplant Congress
Vancomycin Prophylaxis for Prevention of Clostridium difficile Recurrence in Renal Transplant Patients.
Purpose: Clostridium difficile infection (CDI) is higher in solid organ transplant recipients. IDSA/SHEA guidelines do not recommend prophylactic (PROPH) vancomycin (VANC) or metronidazole in CDI…2017 American Transplant Congress
Efficacy of Trimethoprim-Sulfamethoxazole Prophylaxis for Nocardia in Solid Organ Transplant Recipients (SOTRs): Systematic Review and Meta-Analysis.
Background:There are increasing reports of breakthrough Nocardia infection in patients taking Trimethoprim-Sulfamethoxazole (TMP-SMX) prophylaxis post SOT. We performed a meta-analysis to evaluate the effectiveness of…2017 American Transplant Congress
Spousal Transmission of Hepatitis B from a Hepatitis B Core Antibody Positive Liver Transplant Recipient – A Case Report.
University of Maryland Medical Center, Baltimore, MD
IntroductionGiven the shortage of donor organs, hepatitis B core antibody positive (HBcAb+) donors have been utilized to increase access to transplantation. It is well established…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- Next Page »